## Divi's Laboratories Limited (DIVISLAB) Stock Analysis

This report analyzes the provided data for Divi's Laboratories Limited (DIVISLAB) to determine whether it's a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**2. Key Indicators:**

**2.1 Current Price Analysis:**

| Metric             | Value      |
|----------------------|------------|
| Last Price          | 5,841.35   |
| Change              | 20.60      |
| % Change (PChange)  | 0.35%      |
| Previous Close      | 5,820.75   |
| Open                | 5,790.00   |
| Close               | 5,846.75   |
| VWAP                | 5,891.50   |
| Week High           | 6,285.45   |
| Week Low            | 3,350.00   |
| Sector PE           | 84.16      |
| Symbol PE           | 84.16      |


* The current price is slightly above the previous close and open, indicating positive momentum.
* The week's high and low show significant volatility.


**2.2 Financial Performance (Last Five Quarters):**  (All figures in Rs.)

| Quarter Ending     | Income     | Expenditure | Profit After Tax | Diluted EPS |
|----------------------|------------|-------------|-----------------|-------------|
| 30-Sep-2024 (U)    | 240,700    | 167,200     | 51,800           | 19.51       |
| 30-Jun-2024 (U)    | 214,200    | 153,900     | 43,000           | 16.18       |
| 31-Mar-2024 (A)    | 233,800    | 163,800     | 53,100           | 19.99       |
| 31-Dec-2023 (U)    | 190,200    | 141,200     | 35,800           | 13.50       |
| 30-Sep-2023 (U)    | 195,300    | 148,900     | 34,200           | 12.89       |

(U) - Unaudited, (A) - Audited


* Revenue shows some fluctuation but generally an upward trend over the last five quarters.
* Profit after tax also shows a fluctuating but generally upward trend.
* Diluted EPS mirrors the trend in profit after tax.


**2.3 Shareholding Analysis:**

| Date       | Promoter & Promoter Group | Public |
|------------|---------------------------|--------|
| 30-Sep-2023 | 51.93%                     | 48.07% |
| 31-Dec-2023 | 51.92%                     | 48.08% |
| 31-Mar-2024 | 51.92%                     | 48.08% |
| 30-Jun-2024 | 51.90%                     | 48.10% |
| 30-Sep-2024 | 51.89%                     | 48.11% |

* Promoter holding has slightly decreased over the past year, but remains significantly above 50%.


**2.4 Corporate Action Summary:**

* Dividends of Rs. 30 per share have been declared on August 2nd, 2024, August 11th, 2023, and August 11th, 2022.  A dividend of Rs. 20 per share was declared in August 2021.  This indicates a consistent dividend payout policy.  Further historical dividend data is available in the provided data.


**2.5 Volatility and Risk:**

* The week's high and low show significant price volatility, indicating a relatively high-risk investment.  The CM Annual Volatility of 30.76% further supports this.


**2.6 Key Directors and Contact Info:**

(A selection of key personnel is shown below.  Full details are available in the provided data.)

* **Murali Krishna Prasad Divi:** Executive Director-MD
* **Satchandra Kiran Divi:** Executive Director-CEO
* **Rameshbabu Venkata Nimmagadda:** Independent Director, Chairperson & Non-Executive Director

**Registrar and Share Transfer Agent:** Kfin Technologies Private Limited (Contact details available in the provided data)


**3. Structured Output:**  (Sections above fulfill this requirement)


**4. Professional Format:** (The report is formatted professionally with clear headings, subheadings, tables, and bullet points.)


**5. Final Verdict:**

**Hold.**

While Divi's Laboratories shows consistent profitability and a history of dividend payouts, the significant price volatility and slight decrease in promoter holding raise concerns.  The recent financial results show positive trends, but the volatility suggests a need for caution.  Further investigation into the reasons for the price volatility and the slight decrease in promoter holdings would be beneficial before considering a buy recommendation.  The current data does not provide sufficient evidence to confidently recommend a buy.  A "hold" strategy allows for further observation and analysis before making a more informed decision.

**Conclusion:**

Based on the provided financial data, Divi's Laboratories demonstrates consistent profitability and a history of dividend payments. However, the high volatility and slight reduction in promoter holdings warrant a cautious approach.  More information is needed to justify a buy recommendation.
